Seekriz Den

music

[Yakup Ergün @dr_yakupergun]

International Delphi Consensus on a Second Ipsilateral Breast Cancer Event

✅ Repeat lumpectomy + PBI re-irradiation: long interval (preferably ≥5 years), small/unifocal tumor, favorable tumor–breast ratio, clear margins feasible, acceptable cosmesis, and no grade ≥3 late RT toxicity.

➡️ Mastectomy: multicentric disease, unfavorable tumor–breast ratio, inability to achieve clear margins, severe fibrosis/poor cosmesis, or grade ≥3 prior RT toxicity.

HER2+ or TNBC alone are not absolute contraindications to repeat BCT.

https://t.co/z5AdVGt3Ec

[Yakup Ergün @dr_yakupergun]

Thoughts on SERENA-6 is a personal commentary that has not been published in conventional academic journals.

From now on, I will share my personal writings in this format as a protest against a publishing system shaped by arbitrary editorial decisions, editors’ personal biases and conflicts of interest, favoritism within professional networks, excessive article processing charges, and the coercive “publish or perish” culture.

[Rebecca Shatsky, MD @Dr_RShatsky]

In advanced #TNBC and #Her2+ breast cancer, for many it’s not an “if”brain metastases will occur, it’s a “when.” Catching brain disease early can preserve cognitive function and decrease rates of catastrophic complications (herniation/death). We have many effective therapies for breast cancer with CNS disease now and folks can live many many years we need to change with the times and screen!! #bcsm #brainmetastases #Breastcancer

[Yakup Ergün @dr_yakupergun]

sBRCA alterations are not biologically or clinically equivalent to gBRCA mutations. In this large real-world study, shorter CDK4/6i treatment duration was observed only in gBRCA carriers, while patients with sBRCA alterations alone had outcomes similar to BRCA-wildtype patients.

https://t.co/79LZColNsI

[MV Chandrakanth @ChandrakanthMv]

The MONARCH Trials — The Complete Abemaciclib Story

From metastatic HR+/HER2− breast cancer to high-risk early breast cancer, HER2-positive disease, and CDK4/6 inhibitor continuation beyond progression, the MONARCH program has defined the clinical role of abemaciclib across the breast cancer continuum.

This infographic provides a one-glance visual summary of the key MONARCH trials and their major clinical take-home messages.

What trial from the MONARCH program has had the greatest impact on your clinical practice?

#BreastCancer #bcsm #Oncology #MedTwitter #Abemaciclib #CDK46 #MONARCH #MedicalEducation #MVOnco

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Stefania Morganti, MD (@StefiMorganti) shares treatment updates on the management of HER2+ Metastatic Breast Cancer, including @DanaFarber recommendations for first-line and maintenance therapy. #DanaFarberBreastCancerCourse #MBC #BreastCancer #bcsm #MetastaticBreastCancer

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Nancy Lin, MD (@nlinmd), presents on ER+ Metastatic Breast Cancer: #SERDs, #CDK4/6, #PI3K, and novel endocrine agents at the #DanaFarberBreastCancerCourse.
#MBC #BreastCancer

[Yakup Ergün @dr_yakupergun]

#SABCS25 | A-BRAVE translational analysis: Baseline TIL ≥30% predicted benefit from adjuvant avelumab in high-risk early TNBC (3-year DDFS 92% vs 59%). No benefit was seen with lower TIL levels. Evidence for TILs as a predictive IO biomarker continues to grow.

https://t.co/Dtn5wWqoFH

[Yakup Ergün @dr_yakupergun]

@ASCO proposes risk-adapted follow-up after BC:

Low➡️annually

Intermediate➡️every 6–12 mos for 5–10 years

High➡️every 3–6 mos after active treatment, until year 10!

At year 5, reassess risk; switch to annual follow-up only if low-risk criteria are met!

https://t.co/8t5Pd1JIBQ

[MV Chandrakanth @ChandrakanthMv]

Beyond gBRCA: Who Else Responds to Olaparib?

The TBCRC 048 expansion cohorts broaden the role of PARP inhibition beyond germline BRCA.

Key messages:
• Germline PALB2: ORR 75% — outcomes comparable to germline BRCA, supporting olaparib use.
• Somatic BRCA1/2: ORR 36.7% — benefit is present, but patient selection is critical.
• Testing matters: Tissue-confirmed somatic BRCA mutations outperformed cfDNA-only findings (50% vs 10% ORR), highlighting the importance of confirming actionable mutations in tumor tissue whenever feasible.
• Clinical takeaway: Treat gPALB2 similarly to gBRCA. In somatic BRCA, prioritize tissue-confirmed mutations, particularly in the first-line setting.

📖 Tung NM, J Clin Oncol. 2026;44:653-661.

#BreastCancer #PARPInhibitors #Olaparib #BRCA #PALB2 #PrecisionOncology #MedicalOncology #JCO #MVOnco

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent narrative review of the clinical evidence of #abemaciclib in HR+, HER2- #BreastCancer from Dr. Erica Mayer and co-authors.
https://t.co/vzsCegEQKw
@elmayermd @Oncology_Ther

[Dr Rupam Manna MD @DrRupamOncology]

🧬 Every cancer cell survives because it finds a way to repair its DNA.

Understanding DNA repair pathways explains why:
✅ BRCA-mutant tumors respond to PARP inhibitors
✅ dMMR/MSI-H cancers benefit from immunotherapy
✅ Platinum chemotherapy works better in HRD tumors
✅ ERCC1 overexpression predicts platinum resistance
✅ DNA-PK is emerging as a radiosensitization target

From BER, HRR, MMR, NER, NHEJ to the Fanconi pathway, these mechanisms form the foundation of modern precision oncology.

Master the biology—and the therapies become much easier to understand.

#Oncology #PrecisionOncology #CancerBiology #DNADamage #DNARepair #PARPInhibitors #BRCA #HRD #MSI #LynchSyndrome #Immunotherapy #PlatinumChemotherapy #MedicalOncology #HemOnc #OncoTwitter #MedEd #FOAMed #DrNB #DMOncology #CancerConceptsExplained

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out this recent publication on the association of #TumorInfiltratingLymphocyte subtypes with clinical characteristics and prognosis in young women with hormone receptor-positive #BreastCancer.
https://t.co/f9BAKZyn5V

✍️@MeganTesch @CollinsLauraC @NabihahTayob @ShoshRosenberg @KathrynRuddyMD @rtamimi @l_schapira @DrEricWiner @AnnPartridgeMD #AYA #TILs

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New study, led by Dr. Stefania Morganti (@StefiMorganti), now out in @JNCI_Now looking at outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
🔓 https://t.co/eXsy2GEj3n
✍️@DrBBychkovsky @DrKateDibble @KathrynRuddyMD @ShoshRosenberg @CollinsLauraC @l_schapira @PhilipPoorvu @matteolambe @curijoey @ASCOPres @TariKingMD @nlinmd @judygarber5 @NabihahTayob @stolaney1 @AnnPartridgeMD @FilipaLynce #BreastCancer

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New study looking at the Impact of #BreastCancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in Women with Pathogenic BRCA1/2 Variants.
https://t.co/66doeBiTJj
@judygarber5

[MV Chandrakanth @ChandrakanthMv]

EMERALD-1 Final OS Analysis

Durvalumab ± Bevacizumab + TACE in Unresectable Embolization-Eligible HCC (eeHCC)

Key findings
• Previous EMERALD-1 showed a significant PFS benefit.
• Final analysis showed no overall survival benefit with the addition of durvalumab ± bevacizumab to TACE.
• Combination therapy was associated with higher toxicity and treatment discontinuation.
• PFS improvement did not translate into an OS benefit.

Clinical implication
• Improved disease control alone should not be assumed to improve survival in eeHCC.
• Treatment decisions should balance PFS benefit against toxicity, treatment burden, and cost.

Reference
Sangro B, et al. EMERALD-1 Final Overall Survival Analysis. ESMO GI Congress 2026.

#ESMOGI2026 #HCC #LiverCancer #Oncology #MedTwitter #MVOnco

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Check out the recently published Young Women's Breast Cancer Study looking at pregnancy history, recency of childbirth, and outcomes in young women with early-stage #BreastCancer.
👉https://t.co/XKRyt0uICe
@GuiNaderMarta @ShoshRosenberg @DrKateDibble @elmayermd @PhilipPoorvu @KathrynRuddyMD @CollinsLauraC @l_schapira @ValenzaCarmine @NabihahTayob @nellage @DrEricWiner @AnnPartridgeMD #AYA

[MV Chandrakanth @ChandrakanthMv]

Can we move beyond chemotherapy in first-line metastatic TNBC?

The BEGONIA Arms 7 & 8 study evaluated the chemotherapy-free combination of Dato-DXd + durvalumab, demonstrating encouraging activity with:

• ORR: 79%
• Complete response: 12.9%
• Median PFS: 14.0 months
• Median DoR: 17.6 months
• Activity observed across PD-L1 subgroups.

While these phase Ib/II results are highly promising, they are hypothesis-generating. Randomized phase III trials are essential before changing standard clinical practice.

What are your thoughts on the role of ADC–immunotherapy combinations in first-line mTNBC?

Reference: Schmid P et al. BEGONIA Arms 7 & 8. Annals of Oncology. 2026.

#BreastCancer #TNBC #mTNBC #ADCs #Immunotherapy #DatoDXd #Durvalumab #Oncology #MedTwitter #MVOnco

[MV Chandrakanth @ChandrakanthMv]

CARBOPLATIN MATTERS: Beyond pCR—Improving Survival in Early TNBC

Carboplatin has long been regarded as a strategy to increase pathologic complete response (pCR) in early triple-negative breast cancer. The PEARLY trial suggests its benefit extends beyond pCR, with a significant improvement in long-term event-free survival.

Key findings
• 868 patients with stage II–III TNBC
• 5-year EFS: 82.3% vs 75.1%
• Absolute EFS gain: +7.2%
• HR 0.67 (33% relative reduction in EFS events)
• Benefit observed in both neoadjuvant and primary surgery → adjuvant settings
• Higher hematologic toxicity, while quality of life and patient-reported neuropathy were preserved

These findings reinforce carboplatin as an evidence-based chemotherapy intensification strategy in early TNBC, particularly when immune checkpoint inhibitors are unavailable or unsuitable.

Reference: Kim GM, et al. PEARLY Trial. Annals of Oncology. 2026.

#BreastCancer #TNBC #MedicalOncology #Oncology #AnnalsOfOncology #MVOnco

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

New @Nature_NPJ study: Ultra-high tumor mutation burden #BreastCancer: genomic profiling and real-world immunotherapy results.
👉https://t.co/rF3CF0SzI4
@KristinaFanucci @MariyaRozenblit @EthanSokol @maryam_lustberg